Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Yi-Xiang Zhang
Preclinical Activity of Selinexor, an Inhibitor of XPO1, in Sarcoma
Oncotarget
Oncology
Related publications
Selinexor, a First-In-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients With Myelodysplastic Syndromes Refractory to Hypomethylating Agents
Blood
Biochemistry
Immunology
Cell Biology
Hematology
XPO1 Inhibition by Selinexor Induces Potent Cytotoxicity Against High Grade Bladder Malignancies
Oncotarget
Oncology
Preclinical Evaluation of Biomarkers Associated With Antitumor Activity of MELK Inhibitor
Oncotarget
Oncology
Activity of PXD101, a Histone Deacetylase Inhibitor, in Preclinical Ovarian Cancer Studies
Molecular Cancer Therapeutics
Cancer Research
Oncology
Preclinical Antitumor Activity of SST0116CL1: A Novel Heat Shock Protein 90 Inhibitor
International Journal of Oncology
Cancer Research
Oncology
Preclinical Evaluation of Antitumor Activity of the Proteasome Inhibitor MLN2238 (Ixazomib) in Hepatocellular Carcinoma Cells
Cell Death and Disease
Molecular Neuroscience
Immunology
Cell Biology
Cancer Research
Cellular
Medicine
Antitumor Activity of the Polo-Like Kinase Inhibitor, TAK-960, Against Preclinical Models of Colorectal Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma
Molecular Cancer Therapeutics
Cancer Research
Oncology
A Novel PI3K Inhibitor PIK-C98 Displays Potent Preclinical Activity Against Multiple Myeloma
Oncotarget
Oncology
